Fierce Healthcare reported on November 8, 2021, that drug manufacturers cannot unilaterally restrict sales of 340B drugs to contracted pharmacies, but they do not have to provide discounts either, according to two separate rulings by federal judges. The lawsuits were filed by Novo Nordisk, Sanofi, Novartis and United Therapeutics in response to a Biden administration warning to drug makers to walk back restrictions imposed in summer 2020.
